MedTrace Logo

18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

NCT01991977 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2025-10-20

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Conditions

  • Malignant Glioma

Interventions

PROCEDURE

Diffusion Weighted Imaging

Undergo DTI

DRUG

Fluorine F 18 Fluorodopa

Undergo 18F-DOPA-PET

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

PROCEDURE

Perfusion Magnetic Resonance Imaging

Undergo pMRI

PROCEDURE

Positron Emission Tomography

Undergo 18F-DOPA-PET

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Temozolomide

Receive temozolomide

Sponsors & Collaborators

Principal Investigators

  • Debra H. Brinkmann, Ph.,D. · Mayo Clinic in Rochester

  • Nadia N. Laack, M.D. · Mayo Clinic in Rochester

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2019-07-01
Completion
2024-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01991977 on ClinicalTrials.gov